Biotech Companies Driving Psychedelics Industry Forward with Key Research
FN Media Group Presents Microsmallcap.com Market Commentary
NEW YORK, April 13, 2021 /PRNewswire/ -- As an urgent public mental health crisis forces research institutions and governments to seriously examine unconventional mental health solutions, psychedelic assisted therapies are showing huge potential. Now, biotech companies have seen the opportunity, and psychedelics companies are diving into further research to seek out mental health solutions for conditions such as depression, PTSD, and suicidal ideation. Some companies like
Mydecine Innovations Group (NEO:MYCO) (OTCPK:MYCOF),
Compass Pathways (NASDAQ:CMPS),
Numinus Wellness (TSXV:NUMI) (OTCPK:LKYSF), and
Seelos Therapeutics (NASDAQ:SEEL) are also looking into natural medicine initiatives to improve the quality of life of individuals struggling with mental health disorders